Pulse Biosciences (PLSE) Presents Clinical Study Results of Nano-Pulse Stimulation Technology to Clear Benign Lesions at ASLMS

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the podium presentation of four clinical studies of NPS technology at the American Society for Laser Medicine and Surgery (ASLMS) Virtual Annual Meeting taking place on May 15-16, 2021. Recent results will be presented on the use of CellFX’s non-thermal, cellular-specific NPS technology in clinical feasibility and optimization studies designed to address a variety of challenging benign skin lesions.

Nano-Pulse Stimulation (NPS) technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue, which is largely comprised of collagen. The distinct advantages of the NPS mechanism have the potential to improve clinical and aesthetic outcomes by clearing benign lesions where important treatment gaps exist.

Abstracts demonstrating the ability of NPS technology to clear Back Acne, Common Nevi (Moles), Sebaceous Hyperplasia (SH) and Cutaneous Warts will be presented by dermatologic surgeons Dr. Bruce Katz of New York, NY; Dr. Joel Cohen of Denver, CO; Dr. Suzanne Kilmer of Sacramento, CA; and Dr. Ted Lain of Austin, TX, respectively.

Dr. Bruce Katz, Director of JUVA Skin & Laser Center and Clinical Professor of Dermatology at The Icahn School of Medicine at Mount Sinai, New York City, commented, “I am excited that the results from our feasibility study to clear back acne further support the promising efficacy of NPS’ cellular mechanism on the sebaceous glands that contribute to acne eruptions. We were also intrigued to observe a potential effect of acne lesion reduction beyond the treated skin areas, which is encouraging.”

“We are proud to have four abstracts accepted for oral presentation at this prestigious global meeting and applaud our investigators whose rigorous scientific studies provide clinical evidence of the differentiated benefits and broad applicability of NPS technology,” said Ed Ebbers, Executive Vice President and General Manager, Dermatology for Pulse Biosciences. “Their vital learnings are crucial not only to advancing our CellFX procedure in real-world clinical practice with the dermatology thought-leaders currently participating in our controlled commercial launch, but also to expanding interest in NPS technology among the next wave of early adopters.”

NPS Technology Presentations Schedule

“Multi-Center Study of Nano-Pulse Stimulation (NPS) Technology for the Treatment of Moderate-to-Severe Acne Vulgaris of the Back: A Feasibility Study” by Bruce Katz, MD [11:18-11-23 a.m. CT, Sunday, May 16]

• Results demonstrate NPS procedure’s ability to treat moderate-to-severe back acne
• Potential regional effect, extending to acne lesions outside NPS-treated skin areas

“A Feasibility Study of Non-Thermal Nano-Pulse Stimulation (NPS) Technology for Treating Common Nevi” by Joel Cohen, MD [11:23-11:28 a.m. CT, Sunday, May 16]

• Data suggest NPS procedure may be effective for treating common nevus lesions.
• Junctional nevi may have better single-treatment clearance, and compound/ intradermal nevi may require an additional NPS session.

“Lower Energy Settings with Nano-Pulse Stimulation (NPS) Procedure to Treat Sebaceous Hyperplasia Yield High Efficacy and Superior Skin Recovery” by Suzanne Kilmer, MD [11:28-11:33 a.m. CT, Sunday May 16]

• Validates NPS procedure for treating sebaceous hyperplasia
• High efficacy was achieved with greatly reduced energy settings
• Single NPS procedure with lowest setting cleared majority of lesions with low rates of transient skin effects.

“Non-Thermal Nano-Pulse Stimulation (NPS) Procedure for Treating Cutaneous, Non-Genital Warts Shows High Clearance Efficacy with a Single Session” by Ted Lain, MD [11:33-11:38 a.m. CT, Sunday, May 16]

• Applicability of NPS procedure to treat non-genital warts
• Overall complete clearance rate for common warts was 75%
• A majority (81%) of common warts completely cleared using a single session, including recalcitrant warts

A live discussion on NPS technology with the presenting authors will also take place from 11:38-11:43 am CT. Content will be available to registered participants live on the ASLMS website during the conference and on-demand for 60 days after the conference.

You May Also Be Interested In

• Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
• enVVeno Medical (NVNO) Reports Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from VenoValve
• Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study